Glaxo growth hit by fall in US sales

GlaxoSmithKline said today that growth stalled in the second quarter of the year as the group struggled to weather a 13% decline in US sales.

Increased generic competition and the temporary suspension of its Rotarix vaccine hit business in the US, although the fall was offset by emerging markets and Japan as well as £275m (€327.6m) in sales of the pandemic H1N1 vaccine.